926 related articles for article (PubMed ID: 32951093)
21. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
22. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
23. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
24. Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.
Balbo-Mussetto A; Saviolo C; Fornari A; Gottardi D; Petracchini M; Macera A; Lario CV; Gallo T; Tarella C; Cirillo S
Radiol Med; 2017 Aug; 122(8):623-632. PubMed ID: 28421406
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
[TBL] [Abstract][Full Text] [Related]
26. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
27. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients.
Hong GS; Chae EJ; Ryu JS; Chae SY; Lee HS; Yoon DH; Suh C
Cancer Imaging; 2021 Jan; 21(1):5. PubMed ID: 33413685
[TBL] [Abstract][Full Text] [Related]
28. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
29. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
Sasamori H; Uno K; Wu J
Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
[TBL] [Abstract][Full Text] [Related]
32. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
[TBL] [Abstract][Full Text] [Related]
33. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract][Full Text] [Related]
34. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
35. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
36. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
37. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.
Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA
Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179
[TBL] [Abstract][Full Text] [Related]
38. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging.
Kharuzhyk S; Zhavrid E; Dziuban A; Sukolinskaja E; Kalenik O
Eur Radiol; 2020 Jul; 30(7):3915-3923. PubMed ID: 32103366
[TBL] [Abstract][Full Text] [Related]
39. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis.
Rama S; Suh CH; Kim KW; Durieux JC; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 Apr; 218(4):602-613. PubMed ID: 34704461
[No Abstract] [Full Text] [Related]
40. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
Gómez León N; Aguado Bueno B; Herreros Pérez M; León Ramírez LF; Alegre A; Colletti PM; Rubello D; Carreras JL; Delgado Bolton RC
Clin Nucl Med; 2021 Apr; 46(4):310-322. PubMed ID: 33534256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
